Eli Lilly diabetes drug Mounjaro won UK watchdog backing: Bloomberg
Britain: Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.
Mounjaro is expected to become a blockbuster treatment if it is also approved to treat obesity and a U.S. decision on its use for weight loss is expected later this year.
Bloomberg News quoted Helen Knight, director of medicines evaluation at the National Institute for Health and Care Excellence (NICE) as saying that Mounjaro has the potential to "provide an effective and good value treatment option" for people with type 2 diabetes that isn't well controlled by other drugs.
NICE and Lilly did not immediately respond to a Reuters request for comment.
Earlier in July, NICE did not recommend Mounjaro, also known as tirzepatide, saying more evidence was needed before it could be used by the National Health Service. NICE asked Lilly for more data on whether the drug resulted in better weight loss than other drugs belonging to the same class of treatments.
Read also: Europe to face shortage of Eli Lilly diabetes drug Trulicity through September
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.